A carregar...

A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia

BACKGROUND: Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective properties. It has recently been reported that rhuEPO increases frataxin levels in combination with clinical improvement in rhuEPO treated patients with Friedreich ataxia (FRDA)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Santner, Wolfram, Schocke, Michael, Boesch, Sylvia, Nachbauer, Wolfgang, Egger, Karl
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184378/
https://ncbi.nlm.nih.gov/pubmed/25298866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2047981614531573
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!